Zydus Lifesciences share price
You have to be logged in to add this to Watchlist.- ₹913.80(1.20%)May 19, 2025 13:14:34 PM IST
- NSE
- BSE
- Vol : 611.03K (NSE + BSE)Last 20 day avg : 1.20 M
Zydus Lifesciences is trading 1.20% upper at Rs 913.80 as compared to its last closing price. Zydus Lifesciences has been trading in the price range of 919.65 & 902.90. Zydus Lifesciences has given -7.10% in this year & 2.74% in the last 5 days. Zydus Lifesciences has TTM P/E ratio 21.59 as compared to the sector P/E of 24.50.There are 27 analysts who have initiated coverage on Zydus Lifesciences. There are 3 analysts who have given it a strong buy rating & 9 analysts have given it a buy rating. 3 analysts have given the stock a sell rating.The company posted a net profit of 1,023.50 Crores in its last quarter.Listed peers of Zydus Lifesciences include Dr Reddys Laboratories (-0.86%), Lupin (-0.91%), Zydus Lifesciences (1.20%).The Mutual Fund holding in Zydus Lifesciences was at 6.36% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Zydus Lifesciences was at 7.31% in 31 Mar 2025. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on May 19, 2025, 07:44 AM UTC
- Dividend YieldLower than industry0.33Annual dividends as a percentage of the stock price.
- P/BLower than historical values4.58The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values20.05Price-to-earnings ratio based on trailing 12-month earnings
- BetaLow volatility0.55Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.04The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in December quarter by 16.96% from Rs 5269.10 crore to Rs 4505.20 crore, year-on-year
- The company has grown its December quarter profit by 29.62% from Rs 789.60 crore to Rs 1023.50 crore, year-on-year
The debt to equity of the company is higher than the industry median
- R1
- 912.78
- R2
- 937.87
- R3
- 966.33
- S1
- 859.23
- S2
- 830.77
- S3
- 805.68
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Dr Reddys Laboratories | Moderately Bullish | 1,219.95 | -0.86 | 1,01,947.35 | 18.11 | 3.05 | 0.65 | 2.34 |
| Lupin | Bearish | 2,049.55 | -0.91 | 93,585.84 | 28.85 | 5.49 | 0.39 | 11.80 |
| Zydus Lifesciences | Neutral | 913.80 | 1.20 | 91,873.47 | 23.81 | 4.58 | 0.33 | 0.13 |
| Abbott India | Bullish | 30,550.00 | -0.04 | 65,112.14 | 45.91 | 15.34 | 1.55 | 3.73 |
| Alkem Laboratories | Moderately Bullish | 5,386.05 | 3.16 | 64,398.31 | 34.71 | 6.05 | 0.80 | 2.22 |
- Promoter(s) holds a high stake in the company at 74.99%
- Promoter(s) have increased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding has decreased by 0.22 percentage points from previous quarter
- Mutual Funds holding has increased by 0.04 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-20 | Audited Results & Final Dividend |
| 2025-02-05 | Quarterly Results |
| 2024-11-12 | Quarterly Results |
| 2024-08-09 | Quarterly Results |
| 2024-05-17 | Audited Results & Final Dividend |
- IndustryBiotechnology & Drugs
- ISININE010B01027
- BSE Code532321
- NSE CodeZYDUSLIFE
Zydus Lifesciences is trading at 913.80 as on Mon May 19 2025 07:44:34. This is 1.20% upper as compared to its previous closing price of 903.00.
The market capitalization of Zydus Lifesciences is 91873.47 Cr as on Mon May 19 2025 07:44:34.
The average broker rating on Zydus Lifesciences is Hold. The breakup of analyst rating is given below -
- 3 analysts have given a strong buy rating
- 9 analysts have given a buy rating
- 10 analysts have given a hold rating
- 3 analysts have given a sell rating
- 2 analysts have given a strong sell rating
The 52 wk high for Zydus Lifesciences is 1323.90 whereas the 52 wk low is 797.05
Zydus Lifesciences can be analyzed on the following key metrics -
- TTM P/E: 21.59
- Sector P/E: 24.50
- Dividend Yield: 0.33%
- D/E ratio: -
Zydus Lifesciences reported a net profit of 3859.50 Cr in 2024.
The Mutual Fund Shareholding was 6.36% at the end of 31 Mar 2025.